Annual report
3151.TEDINET S100TV6K
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥587.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥578.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥538.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥564.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥4.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥6.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥693m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥8.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥4.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥317.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥297.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥313.0bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥311.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥307.7bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥211.3bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥197.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥105.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥100.0bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥103.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥97.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥34.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥19.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥31.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥29.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥23.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥8.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥549m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥2.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥115.03 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.88 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.26 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.33 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.54 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,085.09 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,911.44 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,858.86 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,863.77 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,753.07 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.3% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 3,705 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 3,719 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 3,754 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 3,696 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 3,579 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥8.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥5.2bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥4.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥8.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.9bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥7.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥4.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥76.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥69.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥69.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥66.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥75.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥23.9bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥20.9bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥52.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥48.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥46.3bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥44.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥43.6bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.6bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.2bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥156.33 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.57 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.04 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.31 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.4 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥32.06 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥42 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥39 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,039.86 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥931.75 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥868.78 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥803.59 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥793.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 68.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 15.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 51,902,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 61,224,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 54 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 54 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 72 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 74 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥94m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥236m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 555 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥7.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥4.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥13.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥109m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥13.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥13.2bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥8.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | ¥90m |
| Medical Products Wholesalereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| Medical Products Wholesalereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Medical Products Wholesalereportable segment | employees | at 2024-03-31 | 2528 pure |
| Medical Products Wholesalereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥563.4bn |
| Medical Products Wholesalereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥552.9bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥10.6bn |
| Medical Products Wholesalereportable segment | segment assets | at 2024-03-31 | ¥297.5bn |
| Medical Products Wholesalereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥67m |
| Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥149m |
| Pharmacy Businessreportable segment | employees | at 2024-03-31 | 526 pure |
| Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥19.1bn |
| Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥19.1bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12m |
| Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥9.5bn |
| Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥310m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥16m |
| Veterinary Drugs Wholesale Businessreportable segment | employees | at 2024-03-31 | 96 pure |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥11.0bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.0bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2024-03-31 | ¥5.4bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥350m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥593.6bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥583.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥10.6bn |
| —segment total | segment assets | at 2024-03-31 | ¥312.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥5.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥5.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥600.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥587.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥13.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥325.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥5.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥836m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥210m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥7.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥9.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥204m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥8.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥175m |
| Medical Products Wholesalereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| Medical Products Wholesalereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.6bn |
| Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥558.1bn |
| Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥547.6bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| Medical Products Wholesalereportable segment | segment assets | at 2023-03-31 | ¥281.6bn |
| Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥57m |
| Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥142m |
| Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥18.4bn |
| Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥9m |
| Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥8.8bn |
| Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥106m |
| Veterinary Drugs Wholesale Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥9m |
| Veterinary Drugs Wholesale Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥17m |
| Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.9bn |
| Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥0 |
| Veterinary Drugs Wholesale Businessreportable segment | segment assets | at 2023-03-31 | ¥5.3bn |
| Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥349m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥587.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥576.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥10.5bn |
| —segment total | segment assets | at 2023-03-31 | ¥295.7bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥4.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥594.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥581.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥305.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥3.8bn |
| Medical Products Wholesalereportable segment | employees | at 2024-03-31 | 54 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,174
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 50252700 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 502527 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 50376 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 51902976 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 502527 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 1599900 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 1599900 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0308 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 1599900 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 1599900 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0308 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 967000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 19.00 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 1154000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 23.00 | |
| Number of male directors and other officers | FilingDateInstant | 12 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.14 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000MuraiTaisukeMember | 107000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000OkamotoSoichiroMember | 152000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000IchijoTakeshiMember | 110000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000IguchiToshiyukiMember | 5000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000SuzukiMitsunaoMember | 158000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000SuzukiKoichiroMember | 1025000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000KitaIsaoMember | 5000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000MatsuiShutaroMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000OnokiKiekoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000KatsuraJunMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000TsugitaMasamiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000JinenHirofumiMember | 23000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000TakahashiSeiyaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E22440-000NishitaniTsuyoshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 1585000 | |
| Audit fees reporting company | Prior1YearDuration | 16000000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
| Audit fees reporting company | CurrentYearDuration | 17000000 | JPY |
| Non audit fees reporting company | CurrentYearDuration | － | JPY |
| Audit fees consolidated subsidiaries | Prior1YearDuration | 60000000 | JPY |
| Non audit fees consolidated subsidiaries | Prior1YearDuration | － | JPY |
| Audit fees consolidated subsidiaries | CurrentYearDuration | 62000000 | JPY |
| Non audit fees consolidated subsidiaries | CurrentYearDuration | － | JPY |
| Audit fees total | Prior1YearDuration | 76000000 | JPY |
| Non audit fees total | Prior1YearDuration | － | JPY |
| Audit fees total | CurrentYearDuration | 79000000 | JPY |
| Non audit fees total | CurrentYearDuration | － | JPY |
| Total amount of remuneration etc remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | 1000000 | JPY |
| Base remuneration remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
| Bonus remuneration etc by category of directors and other officers | CurrentYearDuration_DirectorsExcludingOutsideDirectorsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |